Novo Nordisk (NYSE: NVO) said it will commit up to $100 million to expand its Beijing R&D center. As much as $40 million of that will go to build new labs for diabetes research. The company plans to have the new labs finished late next year and occupy them in 2012. Most of this information is added detail to the company’s September announcement that it would expand its Beijing R&D operation
http://seekingalpha.com/article/237067-novo-nordisk-plans-massive-investment-in-china-r-d-center
The market for diabetes drugs in China is huge 100 million suffer from the disease.
Lilly is building a diabetes research center in Shanghai with a staff of 100 researchers.
Novo Nordisk is still waiting for China approval for Victoza. 8)
http://seekingalpha.com/article/237067-novo-nordisk-plans-massive-investment-in-china-r-d-center
The market for diabetes drugs in China is huge 100 million suffer from the disease.
Lilly is building a diabetes research center in Shanghai with a staff of 100 researchers.
Novo Nordisk is still waiting for China approval for Victoza. 8)
